Officials issue warning after E.coli outbreak is linked to RFK Jr's favorite drink
State health officials have reported 21 illnesses linked to Campylobacter and E. coli linked to unpasteurized milk.
The pasteurization process involves heating milk to about 145 degrees Fahrenheit for 30 minutes, which kills pathogens like E. coli, but raw milk skips this process.
Seven people have been hospitalized due to drinking raw milk contaminated with harmful bacteria from a specific farm in Northeast or Central Florida, but officials did not disclose which one.
'Sanitation practices in this farm are of particular concern due to the number of cases,' the health department said.
According to the health department, infections from Shiga toxin-producing E. coli and Campylobacter can lead to symptoms like diarrhea, vomiting, and stomach cramps. In more serious cases, especially in children, these infections can result in kidney failure.
In Florida, raw milk is legally sold only as pet or animal feed, not for human consumption, which reduces the ability to enforce strict sanitation standards. Labels on containers are required to clearly state that the milk is intended for animal use only.
Health and Human Services Secretary RFK Jr has said he exclusively drinks raw milk. Supporters of the raw milk movement with the Make America Healthy Again push have celebrated his past statements about wanting to tackle the issue of making raw milk legal and more widely available nationwide during his tenure at the agency.
Among the 21 cases of Campylobacter and E. coli in Florida, six were children under 10. Seven of the 21 people affected have been hospitalized but no deaths have been reported as of Monday.
'Floridians are encouraged to use this information to make informed decisions about their health and sources of raw milk should they choose to consume it,' the health department said.
Sales of raw milk are illegal in eight states, while others, such as Florida, allow it with clear distinctions, such as making it for pet use only or available only on farm stands.
Raw milk has garnered a cult-like following among conservatives, who believe each individual should decide what they drink regardless of risk.
Since taking office, Kennedy's FDA paused a quality control program that evaluates labs testing raw milk intended for pasteurization, citing staffing cuts at the health department dating back to the Trump administration.
Despite the pause, store-bought milk remains safe due to strict testing by state and federal agencies and the dairy industry
Many believe the pasteurization process, which involves heating the milk and nothing else, strips it of much of its nutritional value, despite scientific evidence stating otherwise.
Additionally, there are no beneficial bacteria in raw milk, according to the FDA, but it does hose a myriad of dangerous pathogens, including Salmonella, Listeria, and Staphylococcus.
Since pasteurization of milk became routine about a century ago, the US has seen 'greatly reduced milk-borne illnesses,' according to the CDC.
Illness still occurs, though.
Between 1987 and 2010, raw milk and raw milk products caused 133 illness outbreaks, some of which were deadly, according to the FDA.
Some wellness influencers claim that drinking raw milk may help alleviate allergies and illnesses, but these claims lack evidence.
Sales of raw cow's milk are surging in the US, yet states have varying regulations on raw milk, with only a few allowing retail sales in stores and others allowing sales only at farms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
12 minutes ago
- The Independent
RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement
Health Secretary Robert F. Kennedy Jr. is vowing to 'fix' the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists. Health experts and lawyers say updates are needed to help clear a backlog of cases in the Vaccine Injury Compensation Program, created by Congress in 1986 as a no-fault payment system for presumed vaccine injuries. But they also worry Kennedy's changes will reflect his history as a leader in the anti-vaccine movement, which has alternately called for abolishing the program or expanding it to cover unproven injuries and illnesses that aren't connected to vaccines. Kennedy and other critics believe the program is 'too miserly in what it considers to be a vaccine injury,' said Jason Schwartz, a public health expert at Yale University. 'That's created great concern that he could expand what's included.' Anti-vaccine groups have long suggested a link between vaccines and autism, despite scientific consensus that childhood vaccines don't cause the condition. Adding autism to the list of injuries covered by the plan 'would dramatically increase the number of compensable cases, potentially bankrupting it," Schwartz said. Program is credited with saving the U.S. vaccine industry Signed into law under President Ronald Reagan, the compensation program is designed to provide quick, efficient compensation to Americans who report known injuries associated with vaccines, such as rare allergic reactions. At the time of its creation, a number of vaccine-makers were exiting the business due to risks of class action lawsuits. In a recent social media post, Kennedy called the program 'broken' and accused federal lawyers and adjudicators who run it of 'inefficiency, favoritism and outright corruption.' Kennedy didn't specify the changes he's seeking. But some of the people he's enlisted to help have a history of bringing vaccine injury cases. In June, the Department of Health and Human Services awarded a $150,000 contract to an Arizona law firm for 'expertise' in the program. The firm's Andrew Downing, an attorney specializing in vaccine injury cases, was listed in the HHS staff directory for a time. 'We just brought a guy in this week who is going to be revolutionizing the Vaccine Injury Compensation Program,' Kennedy told Tucker Carlson shortly after the award. Revamping the program would be the latest in a string of decisions that have upended U.S. vaccine policy, including this week's cancellation of research funding for vaccines using mRNA technology. Downing and Kennedy have had roles in HPV vaccine lawsuits Downing has had a leading role in lawsuits against Merck alleging injuries from its HPV vaccine, Gardasil, including a rare movement disorder. In a podcast last year for people with the condition, Downing lamented that the injury compensation program 'has taken a hard line' against such cases, leading lawyers to file injury lawsuits in civil court. Approximately 70% of the Gardasil cases against Merck started as claims filed by Downing in the federal injury program, according to court records. A judge dismissed more than 120 of those cases, citing 'a paucity of evidence" that Gardasil caused patients' problems. A spokesman for Kennedy declined to comment on Downing's hiring. Kennedy himself has been involved in the Gardasil litigation, as both an attorney and consultant. Before joining the government, Kennedy received payments for referring potential Gardasil clients to Wisner Baum, one of the law firms suing Merck. Following questions about the agreement during his confirmation hearings, Kennedy agreed to give up his stake in the deal and transfer any future fees to 'a nondependent, adult son," according to his financial disclosures. One of Kennedy's sons is an attorney at Wisner Baum. Experts see need for reform Experts who study vaccine compensation say real changes are needed to modernize the 40-year-old program. The cap on compensation remains $250,000 for injury or death, the same as in 1986. Similarly, the program still has eight adjudicators, known as special masters, to review all cases before the government. On average, the process takes two to three years. The fund has paid out $5.4 billion, compensating about 40% of all people who filed claims. The U.S. has an 'ethical obligation' to promptly pay those harmed by government-recommended vaccines, says Dorit Reiss, a professor at the University of California Hastings College of the Law. 'Plus, I think it increases trust in the vaccination program if you have quick, generous compensation,' Reiss said. One possible change: Adding injuries As health secretary, Kennedy has broad powers to reshape the program. One approach could be adding new diseases and illnesses to the government table of payable injuries. In the early 2000s, the program ruled against more than 5,000 claims from families who said vaccines led to their children's autism, citing hundreds of scientific studies discrediting the link. Critics of Kennedy say he could claim that he has new evidence of harm — perhaps from a large autism study he's commissioned — and add the condition to the program. In response, the federal government might have to increase taxes on vaccines to replenish the compensation fund, which would make the shots more expensive and less accessible. 'Then you will start to watch the vaccine program infrastructure in this country disintegrate until someone steps in,' Dr. Paul Offit, a vaccine researcher at Children's Hospital of Philadelphia who has clashed with Kennedy for years. A recent Senate hearing titled 'Voice of the Vaccine Injured' appeared to make the case for expanding the program. Witnesses included two representatives from Children's Health Defense, the nonprofit group that Kennedy previously chaired and has repeatedly sued the government over vaccines. The group's chief science officer, Brian Hooker, told lawmakers he tried unsuccessfully for 16 years trying to get compensation for his son's autism, which he attributes to the measles-mumps-rubella vaccine. Another possible change: Removing vaccines Another approach would involve removing certain vaccines from the program, making it easier to bring lawsuits against vaccine-makers. Under current law, people claiming injuries from vaccines covered by the program must first pursue a compensation claim before they can sue. In cases where the science doesn't support a connection to vaccines, lawyers might be more successful before a jury. 'Jury trials take advantage of the fact that most jurors don't know anything about science or medicine,' Offit said. 'They are not going to be as easily moved by the data.' Still, attorneys who bring cases before the compensation program say the process has become more burdensome and adversarial over the years. Even small changes could improve things. For instance, the statute of limitations for claims could be extended beyond the current three years, which lawyers say cuts off many potential clients. 'I'm hoping there will be changes put in place that make the program easier for petitioners to navigate' said Leah Durant, a vaccine injury attorney. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Daily Mail
13 minutes ago
- Daily Mail
Ex-New York Giants player Dave Gallagher, who quit football to become a surgeon, dead at 73
A former NFL player who quit football to become an orthopedic surgeon has died at the age of 73, according to a newly-published obituary. Dave Gallagher began his playing career with the Bears in 1974 and suited up for the Giants from 1975-1976. However, the defensive lineman stepped away from the sport following his stint in New York to finish medical school at his alma mater, the University of Michigan, and embark on a career as a surgeon. A cause of death has not been disclosed for Gallagher, who passed away on January 2 according to the obituary. It appears the obituary was not posted until August 4, and a graveside service is scheduled for August 19.
The Independent
42 minutes ago
- The Independent
‘Shock' as study reveals how weight-loss pill stacks up against injections
Eli Lilly 's experimental weight-loss pill delivered a 12.4 per cent body weight reduction in patients over 72 weeks, the pharmaceutical giant announced on Thursday. However, the late-stage study results fell short of Novo Nordisk 's injectable Wegovy, which delivered 14.9 per cent weight loss over 68 weeks in a 2021 trial. Lilly shares plummeted 14 per cent in premarket trading as investor expectations went unmet. Unlike injectable obesity drugs, which are peptides mimicking the appetite-controlling GLP-1 hormone, orforglipron is a small molecule pill. This makes it "easier to manufacture and package," according to Kenneth Custer, president of Lilly's cardiometabolic health division. Lilly, whose injectable GLP-1 Zepbound competes directly with Wegovy, views the once-daily pill as a promising alternative to injections. It "could be used for early intervention and long-term disease management," Custer said – a strategy supported by patient preference for pills due to convenience and a dislike of needles. "We have pretty big aspirations for how many patients orforglipron could help," he said. Custer added that Lilly still expects to file for regulatory approvals of the pill before the end of 2025. The study of overweight or obese adults with weight-related health issues, but not diabetes, included more than 3,000 people. On average, those who received the highest 36-milligram dose of orforglipron shed 12.4 per cent of their weight, versus 0.9 per cent for those who received a placebo. Patients on the 6 mg dose of the Lilly drug lost 7.8 per cent of their weight. After early trial results, expectations were high for the drug to do better than Novo's Wegovy, Barclays analyst Emily Field said. "(But) it's worse than Wegovy so it's a shock." The most common side effects seen in the study were mild-to-moderate gastrointestinal issues. The rate of nausea for high-dose patients was 33.7 per cent, while 24 per cent experienced vomiting, compared with 10.4 per cent and 3.5 per cent, respectively, for the placebo group. At least two analysts said that the tolerability profile of orforglipron also came in below what was seen in the drug's trial with diabetes patients. "While we still see this as a manageable profile, rates of nausea and vomiting may be higher than investor expectations," BMO Capital Markets analyst Evan Seigerman said. Just over 10 per cent of the high-dose patients dropped out of the trial due to adverse side effects. No liver safety issues were seen, Lilly said. At least three analysts said the market had been looking for orforglipron to match Wegovy's results, with some expecting the pill to surpass Novo's popular drug. "That is a best case scenario for Novo ... The competitive threat from Lilly is suddenly much weaker than anticipated," Novo and Lilly shareholder Markus Manns said. Zepbound and Wegovy currently dominate the weight-loss market, which some analysts expect to reach $150 billion by the early 2030s. The U.S. Food and Drug Administration is reviewing a high-dose oral version of Wegovy for potential approval later this year. Novo said it helped overweight or obese adults lose 15 per cent of their body weight in a late-stage trial. Custer said orforglipron can be taken without restrictions on food and water. Lilly said orforglipron also lowered markers of heart disease risk, including cholesterol, triglycerides, and blood pressure, across all doses. Wegovy has been approved to reduce the risk of major heart problems, and Lilly last week released data showing the heart-protective qualities of diabetes treatment Mounjaro, which has the same main ingredient as Zepbound. Heart disease approvals would greatly enhance the likelihood of insurance coverage for weight-loss drugs. The company announced earlier in 2025 that a Phase 3 study found that type 2 diabetes patients lost nearly 8 per cent of their body weight after 40 weeks on orforglipron. Lilly has also said it has begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, which should help avoid shortages experienced when early demand for the injectables far outstripped supply. The full results from the Lilly-backed trial will be presented in September at a major European diabetes meeting, the Indianapolis-based drugmaker said.
